Crinetics Pharmaceuticals (CRNX) Non-Current Deferred Tax Liability (2019 - 2024)

Crinetics Pharmaceuticals has reported Non-Current Deferred Tax Liability for 4 years, with the latest figure at $9.8 million in Q4 2024.

• For the quarter ending Q4 2024, Non-Current Deferred Tax Liability changed 0.49% year-over-year to $9.8 million; the trailing twelve-month figure through Dec 2024 stood at $9.8 million (changed 0.49% YoY), and the FY2024 full-year result was $9.8 million, changed 0.49% from the prior year.
• Non-Current Deferred Tax Liability for Q4 2024 stood at $9.8 million, roughly flat from $9.8 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $9.8 million in Q4 2023, with the low at $453000.0 in Q4 2022.
• Average Non-Current Deferred Tax Liability over 3 years is $6.7 million, with a median of $9.8 million recorded in 2024.
• Year-over-year, Non-Current Deferred Tax Liability surged 2063.13% in 2023 and fell 0.49% in 2024.
• Tracing CRNX's Non-Current Deferred Tax Liability over 3 years: stood at $453000.0 in 2022, then surged by 2063.13% to $9.8 million in 2023, then declined by 0.49% to $9.8 million in 2024.
• The last three Non-Current Deferred Tax Liability figures came in at $9.8 million (Q4 2024), $9.8 million (Q4 2023), and $453000.0 (Q4 2022), per Business Quant data.

Peer Comparison